Neurocrine Biosciences Reports New INGREZZA Data in Tardive Dyskinesia
SAN DIEGO, June 8, 2026 Neurocrine Biosciences announced new clinical findings demonstrating the long-term effectiveness of INGREZZA® (valbenazine) capsules...
Movement Disorders
Advertisement
Galmed to Acquire Colospan in Major GI MedTech Expansion
RAMAT GAN, Israel – June 8, 2026 Galmed Pharmaceuticals has entered into a definitive agreement to acquire Colospan Ltd.,...
Neurocrine Presents New INGREZZA Data Showing Rapid Improvements in Tardive Dyskinesia
SAN DIEGO, California, USA – June 8, 2026 Neurocrine Biosciences has presented new clinician-reported data demonstrating meaningful functional, physical,...
Teva Presents New AUSTEDO Data Supporting Sustained TD Treatment
PARSIPPANY, New Jersey, USA & TEL AVIV, Israel – June 8, 2026 Teva Pharmaceuticals has unveiled new real-world and...
Teva Reports Real-World Benefits of AUSTEDO for Huntington’s Disease Chorea
PARSIPPANY, N.J. and TEL AVIV, Israel, June 5, 2026 Teva Pharmaceuticals announced new real-world data demonstrating that treatment with...
Advertisements
Amneal Reports Positive Phase 4 ELEVATE-PD Results for CREXONT
BRIDGEWATER, N.J., June 5, 2026 Amneal Pharmaceuticals announced positive interim results from the ongoing Phase 4 ELEVATE-PD study, demonstrating...
Teva Reports New AUSTEDO Data in Huntington’s Chorea
PARSIPPANY, N.J. and TEL AVIV, Israel, June 5, 2026 Teva Pharmaceuticals has presented new real-world evidence demonstrating that treatment...
Merz Therapeutics Unveils New Insights Into Parkinson’s OFF Episodes at WPC 2026
FRANKFURT, Germany & RALEIGH, N.C. — May 28, 2026 Merz Therapeutics presented new research at the World Parkinson Congress...
AbbVie Seeks FDA Approval for Tavapadon to Treat Parkinson’s Disease
North Chicago, Ill., September 26, 2025 – AbbVie (NYSE: ABBV) announced the submission of a New Drug Application (NDA)...
Advertisement
